Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

About this update from Jaguar Health, Inc.

[{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / September 23, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, September 25, 2025 at the Emerging Growth Conference and virtually on Tuesday, September 30, 2025 at the Lytham Partners Fall 2025 Conference.","length":350,"tagName":"p"},{"type":"text","content":"Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference","length":98,"tagName":"p","attribs":{}},{"type":"text","content":"When: Thursday, September 25, 2025 from 2:55 - 3:05 PM Eastern Time","length":67,"tagName":"p","attribs":{}},{"type":"text","content":"Where: Online (Click Here)","length":26,"tagName":"p","attribs":{}},{"type":"text","content":"Registration link for conference: Click Here","length":44,"tagName":"p","attribs":{}},{"type":"text","content":"Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"Participation Instructions for Jaguar's Virtual Presentation at the Lytham Partners Fall 2025 Conference","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"When: Tuesday, September 30, 2025 at 3:30 PM Eastern Time","length":57,"tagName":"p","attribs":{}},{"type":"text","content":"Where: Online (Click Here). A replay of the webcast will be available through the same link.","length":92,"tagName":"p","attribs":{}},{"type":"text","content":"About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic ...

More updates from Jaguar Health, Inc.